|
An2 Therapeutics Inc (NASDAQ: ANTX) |
|
An2 Therapeutics Inc
ANTX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
An2 Therapeutics Inc 's sales fell
in the first quarter of 2025 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 4.43 %
An2 Therapeutics Inc net loss decreased from $-17 millions, to $-11 millions in first quarter of 2025,
• More on ANTX's Growth
|
|
An2 Therapeutics Inc realized a net loss in trailing twelve months.
An2 Therapeutics Inc realized cash reduction of $ -0.16 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
• More on ANTX's Valuation
|
|
|
|
|
An2 Therapeutics Inc realized net loss in trailing twelve months.
An2 Therapeutics Inc realized cash outflow of $ -0.16per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
An2 Therapeutics Inc Price to Book Ratio is at 0.45 lower than Industry Avg. of 33.79. and higher than S&P 500 Avg. of 0.01
• More on ANTX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com